Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

Journal of Immunology

Volumn 197, Issue 4, 2016, Pages 1477-1488

  Waugh, Katherine A ^a   Leach, Sonia M ^b   Moore, Brandon L ^a   Bruno, Tullia C ^a   Buhrman, Jonathan D ^a   Slansky, Jill E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PEPTIDE VACCINE; SERYLPROPYLSERYLTYROSYLVALYLTYROSYLHISTIDINYLGLUTAMINYLPHENYLALANINE; THREONYLPROPYLHISTIDINYLPROPYLALANYLARGINYLISOLEUCYLGLYCYLLEUCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MOLECULAR GENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; CELL SEPARATION; DISEASE MODEL; DNA MICROARRAY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; TUMOR ESCAPE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR ESCAPE;

EID: 84983753066     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600589     Document Type: Article

References (96)

1. Galon, J., A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce- Pagès, M. Tosolini, M. Camus, A. Berger, P. Wind, et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
2. Fridman, W. H., F. Pagès, C. Sautès-Fridman, and J. Galon. 2012. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12: 298-306.
3. Schietinger, A., and P. D. Greenberg. 2014. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35: 51-60.
4. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-360.
5. Baitsch, L., S. A. Fuertes-Marraco, A. Legat, C. Meyer, and D. E. Speiser. 2012. The three main stumbling blocks for anticancer T cells. Trends Immunol. 33: 364-372.
6. Yang, Y. 2015. Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest. 125: 3335-3337.
7. Hirano, F., K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D. B. Flies, J. S. Lau, G. Zhu, et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65: 1089-1096.
8. Wolchok, J. D., H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369: 122- 133.
9. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. [Published erratum appears in 2011 J. Exp. Med. 208: 1331.] J. Exp. Med. 207: 2187-2194.
10. Corbett, T. H., D. P. Griswold Jr., B. J. Roberts, J. C. Peckham, and F. M. Schabel Jr. 1977. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40(Suppl): 2660- 2680.
11. Lechner, M. G., S. S. Karimi, K. Barry-Holson, T. E. Angell, K. A. Murphy, C. H. Church, J. R. Ohlfest, P. Hu, and A. L. Epstein. 2013. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J. Immunother. 36: 477-489.
12. Castle, J. C., M. Loewer, S. Boegel, J. de Graaf, C. Bender, A. D. Tadmor, V. Boisguerin, T. Bukur, P. Sorn, C. Paret, et al. 2014. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics 15: 190.
13. Cheever, M. A., J. P. Allison, A. S. Ferris, O. J. Finn, B. M. Hastings, T. T. Hecht, I. Mellman, S. A. Prindiville, J. L. Viner, L. M. Weiner, and L. M. Matrisian. 2009. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15: 5323- 5337.
14. Melero, I., G. Gaudernack, W. Gerritsen, C. Huber, G. Parmiani, S. Scholl, N. Thatcher, J. Wagstaff, C. Zielinski, I. Faulkner, and H. Mellstedt. 2014. Therapeutic vaccines for cancer: An overview of clinical trials. Nat. Rev. Clin. Oncol. 11: 509-524.
15. Huang, A. Y., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93: 9730-9735.
16. McWilliams, J. A., R. T. Sullivan, K. R. Jordan, R. H. McMahan, C. B. Kemmler, M. McDuffie, and J. E. Slansky. 2008. Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine 26: 1863-1873.
17. Baitsch, L., P. Baumgaertner, E. Devêvre, S. K. Raghav, A. Legat, L. Barba, S. Wieckowski, H. Bouzourene, B. Deplancke, P. Romero, et al. 2011. Exhaustion of tumor-specific CD8? T cells in metastases from melanoma patients. J. Clin. Invest. 121: 2350-2360.
18. Jordan, K. R., R. H. McMahan, C. B. Kemmler, J. W. Kappler, and J. E. Slansky. 2010. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. [Published erratum appears in 2010 Proc. Natl. Acad. Sci. USA 107: 4788-4789.] Proc. Natl. Acad. Sci. USA 107: 4652-4657.
19. Jordan, K. R., R. H. McMahan, J. Z. Oh, M. R. Pipeling, D. M. Pardoll, R. M. Kedl, J. W. Kappler, and J. E. Slansky. 2008. Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J. Immunol. 180: 188-197.
20. Overwijk, W. W., D. R. Surman, K. Tsung, and N. P. Restifo. 1997. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods 12: 117-123.
21. Slansky, J. E., F. M. Rattis, L. F. Boyd, T. Fahmy, E. M. Jaffee, J. P. Schneck, D. H. Margulies, and D. M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13: 529-538.
22. Kruisbeek, A. M. 1993. Isolation and fractionation of mononuclear cell populations. In Current Protocols in Immunology. A. M. Kruisbeek, J. E. Coligan, D. H Margulies, E.M. Shevach, and W. Strober, ed. New York:, John Wiley & Sons, Inc., p. 311-315.
23. McMahan, R. H., J. A. McWilliams, K. R. Jordan, S. W. Dow, D. B. Wilson, and J. E. Slansky. 2006. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J. Clin. Invest. 116: 2543-2551.
24. Buhrman, J. D., K. R. Jordan, D. J. Munson, B. L. Moore, J. W. Kappler, and J. E. Slansky. 2013. Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J. Biol. Chem. 288: 33213-33225.
25. Clément-Ziza, M., D. Gentien, S. Lyonnet, J. P. Thiery, C. Besmond, and C. Decraene. 2009. Evaluation of methods for amplification of picogram amounts of total RNA for whole genome expression profiling. BMC Genomics 10: 246.
26. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. Royal Stat. Soc. B 57: 289-300.
27. Tusher, V. G., R. Tibshirani, and G. Chu. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98: 5116-5121.
28. Wu, B. 2005. Differential gene expression detection using penalized linear regression models: The improved SAM statistics. Bioinformatics 21: 1565-1571.
29. Saeed, A. I., V. Sharov, J. White, J. Li, W. Liang, N. Bhagabati, J. Braisted, M. Klapa, T. Currier, M. Thiagarajan, et al. 2003. TM4: A free, open-source system for microarray data management and analysis. Biotechniques 34: 374- 378.
30. Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, and J. P. Mesirov. 2005. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102: 15545-15550.
31. Wherry, E. J., S. J. Ha, S. M. Kaech, W. N. Haining, S. Sarkar, V. Kalia, S. Subramaniam, J. N. Blattman, D. L. Barber, and R. Ahmed. 2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27: 670-684.
32. Parish, I. A., S. Rao, G. K. Smyth, T. Juelich, G. S. Denyer, G. M. Davey, A. Strasser, and W. R. Heath. 2009. The molecular signature of CD8+ T cells undergoing deletional tolerance. Blood 113: 4575-4585.
33. Schietinger, A., J. J. Delrow, R. S. Basom, J. N. Blattman, and P. D. Greenberg. 2012. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335: 723-727.
34. Giordano, M., C. Henin, J. Maurizio, C. Imbratta, P. Bourdely, M. Buferne, L. Baitsch, L. Vanhille, M. H. Sieweke, D. E. Speiser, et al. 2015. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J. 34: 2042-2058.
35. Huang, W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4: 44-57.
36. Huang, W., B. T. Sherman, and R. A. Lempicki. 2009. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37: 1-13.
37. Yeung, K. Y., D. R. Haynor, and W. L. Ruzzo. 2001. Validating clustering for gene expression data. Bioinformatics 17: 309-318.
38. Hartigan, J. A., and M. A. Wong. 1979. Algorithm AS 136: A K-Means Clustering Algorithm. J. Royal Stat. Soc. C. 28: 100-108.
39. Selvaraj, S., and J. Natarajan. 2011. Microarray data analysis and mining tools. Bioinformation 6: 95-99.
40. Thomas, P. D., M. J. Campbell, A. Kejariwal, H. Mi, B. Karlak, R. Daverman, K. Diemer, A. Muruganujan, and A. Narechania. 2003. PANTHER: A library of protein families and subfamilies indexed by function. Genome Res. 13: 2129- 2141.
41. Chang, J. T., and J. R. Nevins. 2006. GATHER: A systems approach to interpreting genomic signatures. Bioinformatics 22: 2926-2933.
42. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12: 492-499.
43. Hernandez, J., S. Aung, W. L. Redmond, and L. A. Sherman. 2001. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med. 194: 707-717.
44. Waugh, K. A., S. M. Leach, and J. E. Slansky. 2015. Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity. Vaccines (Basel) 3: 771-802.
45. Ringnér, M. 2008. What is principal component analysis? Nat. Biotechnol. 26: 303-304.
46. Mootha, V. K., C. M. Lindgren, K. F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstrale, E. Laurila, et al. 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34: 267-273.
47. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188: 2205-2213.
48. Pauken, K. E., and E. J. Wherry. 2015. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36: 265-276.
49. Wherry, E. J., and M. Kurachi. 2015. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15: 486-499.
50. Reichert, T. E., R. Day, E. M. Wagner, and T. L. Whiteside. 1998. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 58: 5344-5347.
51. Wolpert, D. H., and W. G. Macready. 1997. No Free Lunch Theorems for Optimization. IEEE Trans. Evol. Comput. 1: 67-82.
52. Shi, M., T. H. Lin, K. C. Appell, and L. J. Berg. 2009. Cell cycle progression following naive T cell activation is independent of Jak3/common gamma-chain cytokine signals. J. Immunol. 183: 4493-4501.
53. Patsoukis, N., D. Sari, and V. A. Boussiotis. 2012. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle 11: 4305-4309.
54. McKarns, S. C., and R. H. Schwartz. 2005. Distinct effects of TGF-beta 1 on CD4+ and CD8+ T cell survival, division, and IL-2 production: A role for T cell intrinsic Smad3. J. Immunol. 174: 2071-2083.
55. Anderson, A. C. 2014. Tim-3: An emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2: 393-398.
56. Waggoner, S. N., and V. Kumar. 2012. Evolving role of 2B4/CD244 in T and NK cell responses during virus infection. Front. Immunol. 3: 377.
57. Johnston, R. J., L. Comps-Agrar, J. Hackney, X. Yu, M. Huseni, Y. Yang, S. Park, V. Javinal, H. Chiu, B. Irving, et al. 2014. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26: 923-937.
58. Wolthers, K. C., S. A. Otto, S. M. Lens, D. N. Kolbach, R. A. van Lier, F. Miedema, and L. Meyaard. 1996. Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: Regulation by CD4+ T cells. Eur. J. Immunol. 26: 1700-1706.
59. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736.
60. Ladányi, A., B. Somlai, K. Gilde, Z. Fejös, I. Gaudi, and J. Tímár. 2004. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin. Cancer Res. 10: 521-530.
61. Churlaud, G., F. Pitoiset, F. Jebbawi, R. Lorenzon, B. Bellier, M. Rosenzwajg, and D. Klatzmann. 2015. Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy. Front. Immunol. 6: 171.
62. Grosso, J. F., C. C. Kelleher, T. J. Harris, C. H. Maris, E. L. Hipkiss, A. De Marzo, R. Anders, G. Netto, D. Getnet, T. C. Bruno, et al. 2007. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- And tumortolerance systems. J. Clin. Invest. 117: 3383-3392.
63. Mandal, R., and K. Strebhardt. 2013. Plk1: unexpected roles in DNA replication. Cell Res. 23: 1251-1253.
64. Koulintchenko, M., S. Vengrova, T. Eydmann, P. Arumugam, and J. Z. Dalgaard. 2012. DNA polymerase a (swi7) and the flap endonuclease Fen1 (rad2) act together in the S-phase alkylation damage response in S. pombe. PLoS One 7: E47091.
65. Schreiber, M., W. J. Muller, G. Singh, and F. L. Graham. 1999. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18: 1663- 1676.
66. Neganova, I., and M. Lako. 2008. G1 to S phase cell cycle transition in somatic and embryonic stem cells. J. Anat. 213: 30-44.
67. Naito, Y., K. Saito, K. Shiiba, A. Ohuchi, K. Saigenji, H. Nagura, and H. Ohtani. 1998. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58: 3491-3494.
68. Scholzen, T., and J. Gerdes. 2000. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 182: 311-322.
69. Radoja, S., M. Saio, and A. B. Frey. 2001. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J. Immunol. 166: 6074-6083.
70. Zheng, S., J. Moehlenbrink, Y. C. Lu, L. P. Zalmas, C. A. Sagum, S. Carr, J. F. McGouran, L. Alexander, O. Fedorov, S. Munro, et al. 2013. Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1. Mol. Cell 52: 37-51.
71. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
72. Byun, H. J., W. W. Jung, D. S. Lee, S. Kim, S. J. Kim, C. G. Park, H. Y. Chung, and T. Chun. 2007. Proliferation of activated CD1d-restricted NKT cells is down-modulated by lymphocyte activation gene-3 signaling via cell cycle arrest in S phase. Cell Biol. Int. 31: 257-262.
73. Nolz, J. C., G. R. Starbeck-Miller, and J. T. Harty. 2011. Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions. Immunotherapy 3: 1223-1233.
74. Waugh, K. A., S. M. Leach, and J. E. Slansky. 2016. Tolerance of Tumor- Specific T cells in Melanoma Metastases. J. Clin. Cell. Immunol. 7: 7.
75. Dranoff, G. 2011. Experimental mouse tumour models: What can be learnt about human cancer immunology? Nat. Rev. Immunol. 12: 61-66.
76. Rizvi, N. A., M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J. J. Havel, W. Lee, J. Yuan, P. Wong, T. S. Ho, et al. 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124-128.
77. Schumacher, T. N., and R. D. Schreiber. 2015. Neoantigens in cancer immunotherapy. Science 348: 69-74.
78. Stephen, T. L., M. R. Rutkowski, M. J. Allegrezza, A. Perales-Puchalt, A. J. Tesone, N. Svoronos, J. M. Nguyen, F. Sarmin, M. E. Borowsky, J. Tchou, and J. R. Conejo-Garcia. 2014. Transforming growth factor b-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity 41: 427-439.
79. Doering, T. A., A. Crawford, J. M. Angelosanto, M. A. Paley, C. G. Ziegler, and E. J. Wherry. 2012. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 37: 1130-1144.
80. DeGregori, J., and D. G. Johnson. 2006. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr. Mol. Med. 6: 739-748.
81. Field, S. J., F. Y. Tsai, F. Kuo, A. M. Zubiaga, W. G. Kaelin Jr., D. M. Livingston, S. H. Orkin, and M. E. Greenberg. 1996. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85: 549-561.
82. Murga, M., O. Fernández-Capetillo, S. J. Field, B. Moreno, L. R. Borlado, Y. Fujiwara, D. Balomenos, A. Vicario, A. C. Carrera, S. H. Orkin, et al. 2001. Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity 15: 959-970.
83. Li, F. X., J. W. Zhu, J. S. Tessem, J. Beilke, M. Varella-Garcia, J. Jensen, C. J. Hogan, and J. DeGregori. 2003. The development of diabetes in E2f1/E2f2 mutant mice reveals important roles for bone marrow-derived cells in preventing islet cell loss. Proc. Natl. Acad. Sci. USA 100: 12935-12940.
84. Zhu, J.W., D. DeRyckere, F. X. Li, Y. Y.Wan, and J. DeGregori. 1999. A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection. Cell Growth Differ. 10: 829-838.
85. Lissy, N. A., P. K. Davis, M. Irwin, W. G. Kaelin, and S. F. Dowdy. 2000. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 407: 642-645.
86. Galluzzi, L., E. Vacchelli, J. M. Bravo-San Pedro, A. Buqué, L. Senovilla, E. E. Baracco, N. Bloy, F. Castoldi, J. P. Abastado, P. Agostinis, et al. 2014. Classification of current anticancer immunotherapies. Oncotarget 5: 12472- 12508.
87. Patsoukis, N., J. Brown, V. Petkova, F. Liu, L. Li, and V. A. Boussiotis. 2012. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal. 5: Ra46.
88. Brunner, M. C., C. A. Chambers, F. K. Chan, J. Hanke, A. Winoto, and J. P. Allison. 1999. CTLA-4-Mediated inhibition of early events of T cell proliferation. J. Immunol. 162: 5813-5820.
89. Greenwald, R. J., M. A. Oosterwegel, D. van der Woude, A. Kubal, D. A. Mandelbrot, V. A. Boussiotis, and A. H. Sharpe. 2002. CTLA-4 regulates cell cycle progression during a primary immune response. Eur. J. Immunol. 32: 366-373.
90. Workman, C. J., L. S. Cauley, I. J. Kim, M. A. Blackman, D. L. Woodland, and D. A. Vignali. 2004. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J. Immunol. 172: 5450-5455.
91. Woo, S. R., M. E. Turnis, M. V. Goldberg, J. Bankoti, M. Selby, C. J. Nirschl, M. L. Bettini, D. M. Gravano, P. Vogel, C. L. Liu, et al. 2012. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72: 917-927.
92. Nguyen, L. T., and P. S. Ohashi. 2015. Clinical blockade of PD1 and LAG3- potential mechanisms of action. Nat. Rev. Immunol. 15: 45-56.
93. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
94. Kaech, S. M., and R. Ahmed. 2001. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat. Immunol. 2: 415-422.
95. Kinjyo, I., J. Qin, S. Y. Tan, C. J. Wellard, P. Mrass, W. Ritchie, A. Doi, L. L. Cavanagh, M. Tomura, A. Sakaue-Sawano, et al. 2015. Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation. Nat. Commun. 6: 6301.
96. Marinov, G. K., B. A. Williams, K. McCue, G. P. Schroth, J. Gertz, R. M. Myers, and B. J. Wold. 2014. From single-cell to cell-pool transcriptomes: stochasticity in gene expression and RNA splicing. Genome Res. 24: 496-510.